Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

INTRODUCTION: Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. We report the efficacy and safety of first-line ave...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Verschraegen, Claire F, Jerusalem, Guy, McClay, Edward F, Iannotti, Nicholas, Redfern, Charles H, Bennouna, Jaafar, Chen, Franklin L, Kelly, Karen, Mehnert, Janice, Morris, John C, Taylor, Matthew, Spigel, David, Wang, Ding, Grote, Hans Juergen, Zhou, Dongli, Munshi, Neru, Bajars, Marcis, Gulley, James L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7481079/
https://ncbi.nlm.nih.gov/pubmed/32907924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001064
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados